ARTICLE | Clinical News
Piclidenoson: Phase II data
July 18, 2016 7:00 AM UTC
Top-line data from a double-blind, international Phase II trial in 89 patients with ocular hypertension and/or glaucoma showed that twice-daily oral CF101 missed the primary endpoint of reducing IOP f...